Combination of Triple Therapy and Chronic PPI Use May Decrease Risk of Colonic Adenomatous Polyps inHelicobacter pyloriInfection

Aim. The aim of the paper is to determine association betweenH. pyloriand colonic adenomatous polyps and to explore whether treatment or chronic PPI use can mitigate this risk.Methods. This case-control study included 943 patients who hadH. pyloritesting and underwent colonoscopy. Presence of polyps was the outcome of interest, whereas age, sex, race,H. pyloriinfection, triple therapy, and chronic PPI use were independent variables. Multivariate regression analysis was used to calculate odds ratios at 95% confidence intervals. This study was approved by the New York Medical College Institutional Review Board.Results.H. pyloriwas associated with increased odds of colonic adenomatous polyps (adjusted OR 1.43, 95% CI 1.04–1.77), with stronger association among patients older than 50 (OR 1.65, 95% CI 1.18–2.33). Triple therapy (OR 0.69, 95% CI 0.44–1.07) or chronic PPI use (OR 0.69, 95% CI 0.43–1.09) decreased odds of polyp formation. Analysis revealed a statistically significant reduction in patients who received both triple therapy and chronic PPI, lowering the odds by 60% (adjusted OR 0.43, 95% CI 0.27–0.67).Conclusion. There is increased risk of colonic adenomatous polyps amongH. pylori-infected patients. Triple therapy or chronic PPI use may mitigate this risk, with further reduction when these two interventions are combined.